Directors | Aidan Bishop | Executive Director |
Jonathan Morley-Kirk | Non-executive Chairman | |
Celia Li | Non-executive Director | |
Company Secretary | Liga Cirite | |
Registered office of the Company | ||
Independent Auditor | PKF Littlejohn LLP | |
15 Westferry Circus | ||
Canary Wharf | ||
London E14 4HD | ||
Bankers | eWealthGlobal Group Limited | |
17 Broad St | ||
St Helier | ||
Jersey JE2 3RR |
Chairman’s Report | 3 |
Report of the Directors | 4 |
Strategic Report | 9 |
Independent Auditor’s Report to the Members of Amala Foods PLC | 10 |
Statement of Comprehensive Income | 13 |
Statement of Financial Position | 14 |
Statement of Changes in Equity | 15 |
Cash Flow Statement | 16 |
Notes to the Accounts | 17 |
• | Governance- disclose the organisation’s governance around climate-related risks and opportunities | |
• | Strategy- disclose the actual and potential impacts of climate-related risks and opportunities on the organisation’s businesses, strategy and financial planning where such information is material | |
• | Risk Management- disclose how the organisation identifies, assesses and manages climate-related risks | |
• | Metrics and Targets-disclose the metrics and targets used to assess and manage relevant climate-related risks and opportunities where such information is material. |
Appointment | Audit | Remuneration | ||
Position | Date | Committee | Committee | |
Jonathan Morley-Kirk | Non-Executive Chairman | 16 April 2016 | ✔ | ✔ |
Aidan Bishop | Executive Director | 16 April 2016 | ✔ | — |
Celia Li | Non-Executive Director | 17 March 2023 | — | ✔ |
31 Mar 2024 | 31 Mar 2023 | |
£ | £ | |
Executive Directors | ||
Aidan Bishop | — | 100,000 |
Non-executive Directors | ||
Jonathan Morley-Kirk | — | 25,000 |
Celia Li | — | — |
Total Remuneration | — | 125,000 |
Number | % | |
Fiske Nominees Limited* | 114,592,082 | 24.54% |
Hargreaves Lansdowne (Nominees) Limited | 101,633,220 | 21.77% |
Interactive Investor Services Nominees Limited | 39,100,001 | 8.37% |
HSDL Nominees Limited | 38,611,379 | 8.27% |
• | the financial statements, prepared in accordance with the relevant financial reporting framework, give a true and fair view of the assets, liabilities, financial position and profit or loss of the Company; |
• | the strategic report includes a fair review of the development and performance of the business and the position of the Company, together with a description of the principal risks and uncertainties that they face; and |
• | the annual report and accounts, taken as a whole, are fair, balanced and understandable and provide the information necessary for shareholders to assess the Company’s position and performance, business model and strategy. |
• | properly select and apply accounting policies; |
• | present information, including accounting policies, in a manner that provides relevant, reliable, comparable and understandable information; |
• | make judgements and accounting estimates that are reasonable and prudent; |
• | provide additional disclosures when compliance with the specific requirements in UK-adopted IAS is insufficient to enable users to understand the impact of particular transactions, other events and conditions on the entity’s financial position and financial performance; |
• | state that the Company has complied with UK-adopted IAS, subject to any material departures disclosed and explained in the accounts; and |
• | prepare the accounts on the going concern basis unless it is inappropriate to presume that the Company will continue in business. |
• | The Company’s accounts have been prepared in accordance with UK-adopted IAS and give a true and fair view of the assets, liabilities, financial position and profit and loss of the Company. |
• | The annual report includes a fair review of the development and performance of the business and the financial position of the Company, together with a description of the principal risks and uncertainties that they face. |
• | give a true and fair view of the state of the company's affairs as at 31 March 2024 and of its loss for the year then ended; | |
• | have been properly prepared in accordance with UK-adopted international accounting standards; and | |
• | have been properly prepared in accordance with the requirements of the Companies (Jersey) Law 1991. |
• | obtaining the director's going concern assessment and evaluating the appropriateness of this assessments; | |
• | obtaining cashflow forecasts and/or budgets for at least a 12-month period from the anticipated approval of the financial statements, ascertaining the key assumptions in the preparing of this forecast/budget and assessing the reasonableness of such assumptions; | |
• | comparing previous forecasts/budgets to performance to assess the reliability of such forecasts/budgets; | |
• | discussing with management to ascertain where they are on the RTO transaction and obtained evidence of any prospectus being submitted to the FCA and ascertained that the RTO transaction is more likely than not to be complete during the 12 months going concern period; | |
• | ascertaining the repayment dates and other terms in respect of all loans held and; | |
• | reviewing the latest post year-end management accounts and the latest bank statements to ascertain the company's post year-end performance, financial position and cash reserves. |
Key Audit Matter | How our scope addressed this matter |
Carrying value of loan receivable | |
In the financial year ended 31 March 2022, the company advanced $125,000 (£101,189) to the acquisition target (at the time) Terra Rara UK Limited. | Our work in respect of this risk included, but was not limited to: • Evaluating and challenging management's impairment assessment, including the key assumptions and inputs; |
As the balance is overdue for repayment, there is a risk that the loan receivable may not be fully recoverable and thus materially overstated. Additionally, significant judgement is required by the directors in assessing whether expected credit losses are required to be recognised in the financial statements. | • Ensuring that the loan has been appropriately measured as at 31 March 2024 in line with IFRS 9 expected credit loss model assessment; and • Reviewing the disclosures in the financial statements including those relating to estimates and judgements used in the expected credit losses assessment. |
Note 9 in the financial statements sets out further details in respect of these balances and note 3.2 explains the judgements made by the directors in their assessment of the expected credit losses in line with IFRS 9 Financial Instruments. | Based on the audit work performed, the loan is not recoverable at 31 March 2024 as Terra Rara UK Limited was dissolved during the year. The loan receivable has been fully impaired. |
• | proper accounting records have not been kept, or proper returns adequate for our audit have not been received from branches not visited by us; or | |
• | the financial statements are not in agreement with the accounting records and returns; or | |
• | we have not received all the information and explanations we require for our audit. |
• | We obtained an understanding of the company and the sector in which it operates to identify laws and regulations that could reasonably be expected to have a direct effect on the financial statements. We obtained our understanding in this regard through discussion with management, independent research of the Companies (Jersey) Law 1991 and our accumulated knowledge and experience of the industry. | |
• | We determined the principal laws and regulations relevant to the company in this regard to be those arising from the Listing Rules and Disclosure Guidance and Transparency Rules, and the Companies (Jersey) Law 1991. | |
• | We designed our audit procedures to ensure the audit team considered whether there were any indications of noncompliance by the company with those laws and regulations. These procedures included, but were not limited to: | |
- | Discussing with management regarding compliance with laws and regulations by the company; | |
- | Reviewing board minutes; and | |
- | Reviewing Regulatory News Services announcements made. | |
• | We also identified the risks of material misstatement of the financial statements due to fraud. We considered, in addition to the non-rebuttable presumption of a risk of fraud arising from management override of controls, that the potential for management bias was identified in relation to the assessment of the carrying value of the loan receivable. We addressed this by challenging the assumptions and judgements made by management (see the Key audit matters section of our report for further detail). | |
• | As in all of our audits, we addressed the risk of fraud arising from management override of controls by performing audit procedures which included, but were not limited to: the testing of journals; reviewing accounting estimates for evidence of bias; and evaluating the business rationale of any significant transactions that are unusual or outside the normal course of business. | |
Note | 31 Mar 2024 | 31 Mar 2023 | |
£ | £ | ||
Administrative expense | ( | ( | |
Impairment expense | 9 | ( | |
Share-based payments expense | 18 | ( | |
Operating loss | ( | ( | |
Interest and other income | |||
Loan note interest | ( | ( | |
Loss before taxation | ( | ( | |
Income tax expense | 8 | ||
Loss and total comprehensive loss for the year attributable to the owners of the company | ( | ( | |
Loss per share: Basic and diluted loss per share | 16 | ( | ( |
Note | 31 Mar 2024 | 31 Mar 2023 | |
£ | £ | ||
Current assets | |||
Trade and other receivables | 10 | ||
Cash and Cash equivalents | 11 | ||
Current liabilities | |||
Trade and other payables | 13 | ( | ( |
Borrowings | 12 | ( | ( |
( | ( | ||
Net liabilities | ( | ( | |
Deficit | |||
Issued share capital | 16 | ||
Other reserves | 15 | ||
Accumulated losses | ( | ( | |
Total deficit | ( | ( | |
Share | Other | Accumulated | Total | |
capital | reserves | losses | deficit | |
£ | £ | £ | £ | |
At 1 April 2022 | ( | ( | ||
Loss for the year | ( | ( | ||
Total comprehensive loss for the year | ( | |||
Shares to be issued waived | ( | |||
Contingent shares to be issued to Directors | ||||
Expired and cancelled options | ( | |||
Options reserve | ||||
Total transactions with owners | ( | |||
At 31 March 2023 | ( | ( | ||
Loss for the year | ( | ( | ||
Total comprehensive loss for the year | ( | |||
Issue of ordinary shares | ||||
Shares to be issued reserve | ||||
Cancelled share warrants | ( | |||
Total transactions with owners | ( | |||
At 31 March 2024 | ( | ( | ||
Note | 31 Mar 2024 | 31 Mar 2023 | |
£ | £ | ||
Cash flows from operating activities | |||
Loss before tax for the year | ( | ( | |
Adjustments for: | |||
Impairment expense | 9 | ||
Finance cost | |||
Unrealised foreign exchange gain | ( | ||
Contingent shares to be issued to Directors | |||
Share based payment expenses | |||
Movement in trade and other payables | |||
Net cash used in operating activities | ( | ( | |
Cash flows from financing activities | |||
Loan received | 12 | ||
Net cash from financing activities | |||
Net (decrease)/increase in cash at bank | ( | ||
Cash at bank at start of year | |||
Cash at bank at end of year | 11 | ||
2.1 | In issue and effective for years commencing on 01 April 2023 |
2.2 | Standards in issue but not yet effective |
Standard | Impact on initial application | Effective date | |
IAS 7 | Supplier Finance Arrangements | January 1, 2024 | |
IFRS 16 | Lease Liability in a Sale and Leaseback | January 1, 2024 | |
IAS 1 | Non-current Liabilities with Covenants | January 1, 2024 |
2.3 | Going concern |
31 Mar 2024 | 31 Mar 2023 | |
£ | £ | |
Borrowings | 1,092,569 | 1,172,719 |
3.1 | Share-based payments |
3.2 | Impairment of financial assets |
3.3 | Post year-end settlement of convertible loan notes |
31 Mar 2024 | 31 Mar 2023 | |
£ | £ | |
Loss before taxation has been arrived at after charging: | ||
Auditor’s remuneration | 37,400 | 37,400 |
Directors’ remuneration* | — | 125,000 |
Share-based payments expense | — | 16,441 |
Write-off of Terra Rara UK advance receivable | 101,189 | - |
31 Mar 2024 | 31 Mar 2023 | |
£ | £ | |
Directors’ emoluments during the year | — | 125,000 |
Total Directors emoluments | — | 125,000 |
31 Mar 2024 | 31 Mar 2023 | |
Directors | 3 | 2 |
Average employees during the year | 3 | 2 |
31 Mar 2024 | 31 Mar 2023 | |
£ | £ | |
Loss before taxation | (334,774) | (440,076) |
Jersey Corporation Tax at 0% | — | — |
Total tax charge* | — | — |
31 Mar 2024 | 31 Mar 2023 | |
£ | £ | |
Write-off of advance receivable, net - Terra Rara UK Ltd. | 101,189 | — |
Total impairment | 101,189 | — |
31 Mar 2024 | 31 Mar 2023 | |
£ | £ | |
Loan Receivables* | - | 101,189 |
Balance at end of year | — | 101,189 |
31 Mar 2024 | 31 Mar 2023 | |
£ | £ | |
Cash at bank | 98,794 | 318,217 |
Balance at end of year | 98,794 | 318,217 |
31 Mar 2024 | 31 Mar 2023 | |
£ | £ | |
Borrowings | 1,092,569 | 1,172,719 |
Balance at end of year | 1,092,569 | 1,172,719 |
31 Mar 2024 | 31 Mar 2023 | |
£ | £ | |
Trade payables | 74,600 | 83,109 |
Accruals | 172,848 | 60,340 |
Balance at end of year | 247,448 | 143,449 |
31 Mar 2024 | 31 Mar 2023 | |
£ | £ | |
Trade and other receivables | — | 101,189 |
Cash and cash equivalents | 98,794 | 318,217 |
Balance at end of year | 98,794 | 419,406 |
31 Mar 2024 | 31 Mar 2023 | |
£ | £ | |
Trade and other payables | 247,448 | 143,449 |
Borrowings | 1,092,569 | 1,172,719 |
Balance at end of year | 1,340,017 | 1,316,168 |
31 Mar 2024 | 31 Mar 2023 | |
£ | £ | |
Trade and other receivables* | — | 101,189* |
Cash and cash equivalents | 98,794 | 318,217 |
98,794 | 419,406 |
• | Reserves - including warrants, options and shares to be issued reserves related to the value of equity that investors have secured as part of their funding provided to the Company and that management has agreed to issue for settlement of remuneration; | |
• | Share capital - represents the nominal value of shares issued; | |
• | Unissued share capital - reflects the value of equity that management has agreed to issue for settlement of remuneration, liabilities and funding provided; and | |
• | Accumulated losses - comprise the Company’s cumulative accounting profits and losses since inception. |
31 Mar 2024 | 31 Mar 2023 | |
£ | £ | |
Warrants reserve | — | 381,159 |
Shares to be issued reserve | 279,945 | 279,939 |
Balance at end of year | 279,945 | 661,098 |
31 Mar 2024 | 31 Mar 2023 | |||
Amount | Amount | |||
Shares* | £ | Shares* | £ | |
Opening balance | 443,620,823 | 6,488,490 | 443,620,823 | 6,488,490 |
Ordinary shares - new shares issued during the period | 23,299,314 | 80,150 | — | — |
Balance at end of year | 466,920,137 | 6,568,640 | 443,620,823 | 6,488,490 |
31 Mar 2024 | 31 Mar 2023 | |
£ | £ | |
Basic and diluted loss per share | (0.0007) | (0.0010) |
Loss used to calculate basic and diluted earnings per share | (334,774) | (440,076) |
Weighted average number of shares used in calculating basic and diluted | ||
earnings per share | 465,767,973 | 443,620,823 |
No. | No. lapsed or | No. outstanding | |||
Exercise price | No. issued | exercised | re-negotiated | and exercisable | Expiry date |
Issued in the year ended 31 Mar 2021 | |||||
1.35p | 4,324,320 | — | — | 4,324,320 | 19 October 2023 |
1.10p | 5,404,400 | — | — | 5,404,400 | 19 November 2023 |
Issued in the year ended 31 Mar 2022 | |||||
1.15p | 43,478,260 | — | — | 43,478,260 | 16 July 2025 |
Transactions during the year ended 31 Mar 2024 | |||||
1.35p | — | — | (4,324,320) | (4,324,320) | 19 October 2023 |
1.10p | — | — | (5,404,400) | (5,404,400) | 19 November 2023 |
1.15p | — | — | (43,478,260) | (43,478,260) | 16 July 2025 |
Balance at end of year | 53,206,980 | — | (53,206,980) | — | |